Discovery of 3-(((9H-purin-6-yl)amino)methyl)-4,6-dimethylpyridin-2(1H)-one derivatives as novel tubulin polymerization inhibitors for treatment of cancer

被引：11
|
作者：
Zhang, Qiangsheng [1 ,2 ,3 ]
Hu, Xi [1 ,2 ,3 ]
Wan, Guoquan [1 ,2 ,3 ]
Wang, Jia [1 ,2 ,3 ]
Li, Lu [1 ,2 ,3 ]
Wu, Xiuli [1 ,2 ,3 ]
Liu, Zhihao [1 ,2 ,3 ]
Yu, Luoting [1 ,2 ,3 ]
机构：
[1] Sichuan Univ, West China Med Sch, West China Hosp, State Key Lab Biotherapy, 17 3rd Sect,Ren Min South Rd, Chengdu 610041, Sichuan, Peoples R China
[2] Sichuan Univ, West China Med Sch, West China Hosp, Canc Ctr, 17 3rd Sect,Ren Min South Rd, Chengdu 610041, Sichuan, Peoples R China
[3] Collaborat Innovat Ctr Biotherapy, 17 3rd Sect,Ren Min South Rd, Chengdu 610041, Sichuan, Peoples R China
来源：
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2019年 / 184卷
关键词：
Microtubule; Tubulin polymerization inhibitors; Anti-cancer agents; Colorectal carcinoma; BIOLOGICAL EVALUATION; CELL-GROWTH; POTENT; DESIGN; ANALOGS; TARGET; IDENTIFICATION; MICROTUBULES; RESISTANCE; PURINES;
D O I：
10.1016/j.ejmech.2019.111728
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
A new series of 3-(((9H-purin-6-yl)amino)methyl)-4,6-dimethylpyridin-2(1H)-one derivatives were designed, synthesized and demonstrated to act as tubulin polymerization inhibitors. These new derivatives showed significant antitumor activities, among which SKLB0533 demonstrated to be the most potent compound, with IC50 values ranging from 44.5 to 135.5 nM against seven colorectal carcinoma (CRC) cell lines. Remarkably, SKLB0533 exhibited no activity against other potential targets, such as 420 kinases and EZH2. Besides, SKLB0533 inhibited tubulin polymerization, arrested the cell cycle at the G2/M phase and induced apoptosis in CRC cells. Furthermore, SKLB0533 suppressed tumour growth in the HCT116 xenograft model without inducing notable major organ-related toxicity, suggesting that SKLB0533 could be used as a promising lead compound for the development of new antitumor agents. (C) 2019 Elsevier Masson SAS. All rights reserved.
引用
收藏
页数：16
相关论文
共 50 条
  • [41] Cytoprotective Activity of Newly Synthesized 3-(Arylmethylamino)-6-Methyl-4-Phenylpyridin-2(1H)-Ones Derivatives
    Sergazy, Shynggys
    Shulgau, Zarina
    Zhulikeyeva, Aigerim
    Ramankulov, Yerlan
    Palamarchuk, Irina, V
    Kulakov, Ivan, V
    MOLECULES, 2022, 27 (17):
  • [42] A simple route to novel 3-(5-amino-1H-pyrazol-4-yl)-5-methyl-4H-1,2,4-triazoles
    Vanden Eynde, JJ
    Estiévenart, L
    Van Haverbeke, Y
    HETEROCYCLIC COMMUNICATIONS, 2000, 6 (05) : 415 - 420
  • [43] 3-[(2-Chloro-6-methylquinolin-3-yl)methyl]quinazolin-4(3H)-one
    Roopan, S. Mohana
    Khan, F. Nawaz
    Kone, Sriramakrishnaswamy
    Hathwar, Venkatesha R.
    Akkurt, Mehmet
    ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE, 2010, 66 : O1545 - U340
  • [44] Crystal structure of 3-{1-[(1-allyl-1H-indazol-6-yl)amino]ethylidene}-6-methyl-2H-pyran-2,4(3H)-dione
    El Ghozlani, Mohamed
    Rakib, El Mostapha
    Gamouh, Ahmed
    Saadi, Mohamed
    El Ammari, Lahcen
    ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS, 2014, 70 : O1256 - +
  • [45] Discovery of 2-Amino-4H-1, 3, 4-thiadiazine-5(6H)-one Derivatives and Their In Vitro Antitumor Investigation
    Mohammed, Faten Zahran
    Rizzk, Youstina William
    El-Deen, Ibrahim Mohey
    Gad, Emad M.
    El Behery, Mohammed
    Mahdy, Ahmed R. E.
    CHEMISTRYSELECT, 2022, 7 (07):
  • [46] MEDI 363-Discovery and SAR of a series of 3-[(6-piperidine-4-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridin-2-ones as IGF-1 receptor kinase inhibitors
    Liu, Peiying
    Velaparthi, Upender
    Wittman, Mark D.
    Saulnier, Mark G.
    Zimmermann, K.
    Sang, Xiaopeng
    Frennesson, David B.
    Lee, Francis Y.
    Carboni, Joan
    Greer, Ann
    Li, Aixin
    Attar, Ricardo
    Gottardis, Marco
    Yang, Zheng
    Vyas, Dolatrai M.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 234
  • [47] Synthesis of 4-hydroxy-3-[(E)-2-(6-substituted-9H-purin-9-yl)vinyl]coumarins as lipoxygenase inhibitors
    Kallitsakis, Michael G.
    Hadjipavlou-Litina, Dimitra J.
    Peperidou, Aikaterini
    Litinas, Konstantinos E.
    TETRAHEDRON LETTERS, 2014, 55 (03) : 650 - 653
  • [48] Discovery of (Z)-1-(3-((1H-Pyrrol-2-yl)methylene)-2-oxoindolin-6-yl)-3-(isoxazol-3-yl)urea Derivatives as Novel and Orally Highly Effective CSF-1R Inhibitors for Potential Colorectal Cancer Immunotherapy
    Lv, Qi
    Pan, Xiang
    Wang, Dan
    Rong, Quanjin
    Ma, Ben
    Xie, Xiaolong
    Zhang, Yinan
    Wang, Junwei
    Hu, Lihong
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (23) : 17184 - 17208
  • [49] Discovery of 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)-phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a Potent, Selective, and Orally Available Mammalian Target of Raparnycin (mTOR) Inhibitor for Treatment of Cancer
    Liu, Qingsong
    Wang, Jinhua
    Kang, Seong A.
    Thoreen, Carson C.
    Hur, Wooyoung
    Ahmed, Tausif
    Sabatini, David M.
    Gray, Nathanael S.
    JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (05) : 1473 - 1480
  • [50] The Discovery of PLK4 Inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as Novel Antiproliferative Agents
    Laufer, Radoslaw
    Forrest, Bryan
    Li, Sze-Wan
    Liu, Yong
    Sampson, Peter
    Edwards, Louise
    Lang, Yunhui
    Awrey, Donald E.
    Mao, Guodong
    Plotnikova, Olga
    Leung, Genie
    Hodgson, Richard
    Beletskaya, Irina
    Mason, Jacqueline M.
    Luo, Xunyi
    Wei, Xin
    Yao, Yi
    Feher, Miklos
    Ban, Fuqiang
    Kiarash, Reza
    Green, Erin
    Mak, Tak W.
    Pan, Guohua
    Pauls, Henry W.
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (15) : 6069 - 6087
12345